Calanolide A
Chemical compoundComposé chimique
Calanolide A is an experimental non-nucleoside reverse transcriptase inhibitor (NNRTI).
Chemical compoundComposé chimique
Calanolide A is an experimental non-nucleoside reverse transcriptase inhibitor (NNRTI).
Chemical compoundComposé chimique
Nobody has pulled this card yet. The first copy makes you its discoverer.
Calanolide A is an experimental non-nucleoside reverse transcriptase inhibitor (NNRTI). This compound was extracted from the tree Calophyllum lanigerum, of variety austrocoriaceum, in Lundu, Malaysian state of Sarawak in 1992 by United States National Cancer Institute (NCI). Due to rarity of the raw materials and low yield of the active ingredient, total synthesis of the compound was devised in 1996. For the same reason, its sister compound (-)-Calanolide B have been touted as replacement. As a result of the discovery of Calanolide A, Sarawak Medichem pharmaceuticals company was established as a joint venture between US-based MediChem Research Inc and Craun Research Sdn Bhd, a company owned by the Sarawak state government. In 2006, Craun Research acquired Sarawak MediChem. In 2016, Craun Research announced the completion of Phase I clinical trials for Calanolide A.
No sale yet.
None on the Market right now.